WEDNESDAY, Sept. 18 (HealthDay News) -- In women with early
breast cancer, three weeks of high-dose radiation is as effective
as the current standard -- five weeks of lower-dose treatment,
British researchers say.
A short course of radiation given in larger doses -- an approach
called hypofractionated radiation -- is safe and effective and
causes less damage to healthy surrounding tissue, according to the
10-year results of two British trials. The short course is also
more convenient and less expensive.
"For most indications, a three-week course of postoperative radiotherapy can be recommended as standard of care for women with early breast cancer following breast conservation surgery or mastectomy," said study researcher Dr. John Yarnold, a professor of clinical oncology at the Institute of Cancer Research in London.
"Three weeks of treatment is gentler on the healthy tissues without loss of anti-cancer effect, so it represents an improvement for women with early breast cancer," he added.
The report, published Sept. 19 in
The Lancet Oncology, may not change current practice
immediately, however, said Dr. Stephanie Bernik, chief of surgical
oncology at Lenox Hill Hospital in New York City.
The short course is "a great alternative and may eventually
replace long-term radiation," Bernik said. But she thinks studies
conducted in the United States are needed to convince U.S.
oncologists of the benefits.
"They want a little experience with it before they start doing it automatically," she added. "But you will probably see it more and more."
Already, some places in the United States use the three-week
course, she said, adding, "we have been waiting for the results of
a long-term study."
In this case, between 1999 and 2002, researchers conducted two
trials -- U.K. Standardization of Breast Radiotherapy, known as
START A and B. The trials tested different radiation doses and
timing schedules among 4,451 women treated at 35 centers across the
START A compared the international standard -- a total of 50 Gy
given in 25 small doses over five weeks -- with two other
schedules: 41.6 Gy and 39 Gy, each given in 13 treatments over five
START B compared the international standard with 40 Gy given in
15 doses of 2.67 Gy over three weeks.
Over 10 years of follow-up, the results of START A were similar
regardless of the dose of radiation. In all three cases, the cancer
relapse rate was about the same, ranging from 6.3 percent to 8.8
percent. Damage to surrounding tissue was also similar regardless
of the dose of radiation, the researchers noted.
In START B, similar results were also seen after 10 years, with
relapses ranging from 5.5 percent to 4.3 percent. Damage to
surrounding tissue, however, was significantly less than in START
A, the researchers found.
The outcomes of the two trials were independent of age, tumor
grade, stage, chemotherapy use, or use of tumor bed boost --
additional radiation therapy, the study authors pointed out.
For more information on breast cancer, visit the
American Cancer Society.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.